Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara-CyBorD for Rare Monoclonal Gammopathies of Renal Significance
NCT06771180Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of daratumumab in monoclonal gammopathy of renal significance (MGRS), proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), light chain proximal tubulopathy (LCPT), thrombotic microangiopathy (TMA), cryoglobulinemic glomerulonephritis, sponsored by Peking University People's Hospital. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
monoclonal gammopathy of renal significance (MGRS)proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID)light chain proximal tubulopathy (LCPT)thrombotic microangiopathy (TMA)cryoglobulinemic glomerulonephritis
Beyond the preview
Go deeper on NCT06771180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771180.